- Home
- PML vs REPL Comparison
PML vs REPL Comparison
Compare PML & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PML
- REPL
- Stock Information
- Founded
- PML 2002
- REPL 2015
- Country
- PML United States
- REPL United States
- Employees
- PML N/A
- REPL N/A
- Industry
- PML Investment Managers
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- PML Finance
- REPL Health Care
- Exchange
- PML Nasdaq
- REPL Nasdaq
- Market Cap
- PML 570.5M
- REPL 578.4M
- IPO Year
- PML N/A
- REPL 2018
- Fundamental
- Price
- PML $7.52
- REPL $8.00
- Analyst Decision
- PML
- REPL Strong Buy
- Analyst Count
- PML 0
- REPL 6
- Target Price
- PML N/A
- REPL $20.00
- AVG Volume (30 Days)
- PML 188.0K
- REPL 967.9K
- Earning Date
- PML 01-01-0001
- REPL 05-15-2025
- Dividend Yield
- PML 5.65%
- REPL N/A
- EPS Growth
- PML N/A
- REPL N/A
- EPS
- PML N/A
- REPL N/A
- Revenue
- PML N/A
- REPL N/A
- Revenue This Year
- PML N/A
- REPL $31.16
- Revenue Next Year
- PML N/A
- REPL N/A
- P/E Ratio
- PML N/A
- REPL N/A
- Revenue Growth
- PML N/A
- REPL N/A
- 52 Week Low
- PML $6.92
- REPL $4.92
- 52 Week High
- PML $9.46
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- PML 33.68
- REPL 36.82
- Support Level
- PML $7.17
- REPL $6.44
- Resistance Level
- PML $8.17
- REPL $7.97
- Average True Range (ATR)
- PML 0.17
- REPL 0.73
- MACD
- PML -0.02
- REPL 0.08
- Stochastic Oscillator
- PML 38.10
- REPL 41.47
About PML Pimco Municipal Income Fund II of Beneficial Interest
PIMCO Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal income tax. The fund portfolio of investments consists of investments in different sectors such as education, healthcare, and others.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.